Compare Biogen Inc (BIIB) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Upstart Holdings Inc — how do they compare? Biogen Inc trades at $192.5 (market cap $28.34B), while Upstart Holdings Inc trades at $32.27 (market cap $3.04B). The key difference: Biogen Inc is far larger — about 9.3× Upstart Holdings Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | UPST | |
|---|---|---|
Market Cap | $28.34B | $3.04B |
Sector | Health | Financials |
52-Week High | $216.63 | $84.13 |
52-Week Low | $122.68 | $24.22 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
UPST trades at $31.46, down 3.91% on the day, reflecting recent volatility amid mixed earnings. The stock shows a bearish technical trend with support near $29, while fundamentals highlight a return to profitability in 2025 with $1.02B revenue and $53.60M net income. Recent news emphasizes AI lending growth and a key $600M funding deal with Neuberger Berman, though margin pressures persist.
The outlook hinges on execution of AI-driven lending expansion and funding stability, with a consensus price target of $42.00 suggesting 33% upside. Risks include earnings volatility, high debt levels, and competitive fintech pressures. Analyst sentiment is balanced with 45% buy ratings, but investors await Q2 2026 results on August 4 for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
